When depression has not improved after multiple medication trials, the question often changes from “What else can I try?” to “What actually works, and how quickly?” That is where the conversation around Spravato versus ketamine treatment usually begins. Both are associated with rapid-acting relief for some patients with treatment-resistant depression, but they are not the same treatment, and those differences matter.
For patients and families weighing next steps, the right choice is rarely about hype. It is about diagnosis, safety, access, medical oversight, and what gives you the best chance of meaningful improvement without adding unnecessary risk.
Spravato versus ketamine treatment: what is the difference?
Spravato is the brand name for esketamine, a prescription nasal spray approved by the FDA for adults with treatment-resistant depression and for adults with major depressive disorder with acute suicidal thoughts or behaviors in specific treatment settings. It is derived from ketamine but is not identical to generic ketamine.
Ketamine treatment for depression usually refers to racemic ketamine, most often given by IV infusion, though some clinics may use other forms. Unlike Spravato, ketamine is not FDA approved specifically for depression. It is commonly used off-label, which is legal and sometimes clinically appropriate, but it does change the regulatory and monitoring framework around treatment.
That distinction alone does not make one automatically better than the other. It does mean the patient experience, cost structure, insurance coverage, and clinical pathways can look very different.
How each treatment works in the brain
Traditional antidepressants often target serotonin, norepinephrine, or dopamine and can take weeks to show benefit. Spravato and ketamine work differently. They affect glutamate signaling and NMDA receptor activity, which may help support faster changes in mood-related brain circuits.
For some patients, that difference is the reason these treatments become part of the conversation at all. When depression has remained severe despite standard approaches, a treatment with a different mechanism can offer a more hopeful path forward.
Still, faster does not mean instant or universal. Some people notice improvement within hours or days. Others need multiple sessions before a change becomes clear. And some patients do not respond enough to justify continuing. A careful psychiatric evaluation helps set realistic expectations before treatment starts.
Why FDA approval changes the conversation
One of the biggest differences in Spravato versus ketamine treatment is the level of FDA oversight tied to depression care.
Spravato went through formal trials for depressive disorders and is administered under a Risk Evaluation and Mitigation Strategy, or REMS, program. That means treatment must occur in a certified medical setting with monitoring after each dose. Patients cannot take it home. This structure adds safety and consistency, especially for people who already feel vulnerable after a long struggle with depression.
Ketamine clinics may also monitor patients closely, and many do so responsibly, but the standards can vary more from one setting to another because ketamine for depression is typically an off-label use. That does not mean ketamine is unsafe. It means the quality of evaluation, monitoring, psychiatric follow-up, and treatment planning becomes even more important.
For patients who value a highly structured, psychiatry-led pathway, FDA-approved treatment often feels more reassuring.
What treatment sessions are actually like
Spravato is given as a nasal spray in a medical office under supervision. After dosing, patients stay for observation, usually around two hours, because temporary side effects can include dissociation, dizziness, nausea, sedation, and increased blood pressure. Patients need transportation home and should not drive until the next day after a restful sleep.
IV ketamine treatment also requires in-office monitoring. A patient receives an infusion over a set period, often 40 minutes, followed by observation. Some people prefer the infusion model because dosing can be adjusted more precisely during treatment. Others prefer the convenience and less invasive nature of a nasal spray.
In practical terms, both options require time, transportation planning, and a willingness to receive treatment in a monitored setting. Neither is a quick errand between appointments.
Which is more effective for depression?
This is often the first question patients ask, and the honest answer is that it depends.
Both Spravato and ketamine have shown promise for treatment-resistant depression. Ketamine has a longer history of off-label psychiatric use and a substantial body of research behind it. Spravato has the advantage of FDA approval for specific depressive conditions and a standardized treatment protocol.
Some studies and clinical experience suggest IV ketamine may produce strong and sometimes rapid antidepressant effects. Spravato also helps many patients, especially when used as part of a broader treatment plan that includes psychiatric follow-up and an oral antidepressant when indicated.
But response is not just about the molecule. It is also about whether the diagnosis is correct, whether bipolar depression has been ruled out or managed appropriately, whether substance use is a factor, whether anxiety or trauma is complicating the picture, and whether the treatment is delivered in a setting that can adjust the plan when needed.
For that reason, the better question is often not “Which one is strongest?” but “Which one is the safer and more appropriate fit for my situation?”
Spravato versus ketamine treatment for safety and monitoring
Safety deserves more attention than marketing claims.
Both treatments can cause short-term side effects such as dissociation, blood pressure changes, nausea, dizziness, and sedation. Both require screening for medical and psychiatric factors that may increase risk. A history of uncontrolled hypertension, certain cardiovascular conditions, psychosis, or active substance misuse may change whether treatment is appropriate or how it should be supervised.
Spravato has a built-in monitoring framework because of the REMS program. That does not remove all risk, but it does create a consistent process. Ketamine safety depends heavily on the clinic, the prescriber, and how carefully the patient is evaluated and followed over time.
This matters because depression treatment should not be reduced to a transaction. The best outcomes usually come from comprehensive care that tracks symptom improvement, side effects, medication interactions, and next-step planning.
Cost and insurance coverage
Cost is one of the most practical differences between these options.
Spravato is more likely than off-label ketamine to have insurance coverage, particularly when a patient meets criteria for treatment-resistant depression and treatment is provided through a certified program. Coverage still varies, and patients may face copays, deductibles, or prior authorization requirements, but the pathway is generally more established.
Ketamine infusions are often self-pay. For some patients, that creates a major barrier, especially because treatment commonly involves a series of sessions rather than a single visit. A lower upfront price at one clinic may not reflect the full cost of maintenance care, follow-up, or coordination with psychiatric treatment.
If affordability is part of the decision, it is worth asking not just about the price per session but about the expected full course of care.
Who may be a good candidate?
Adults with treatment-resistant depression are often the main candidates for either option, but candidacy should never be decided by symptoms alone. A thorough psychiatric assessment should review diagnosis, treatment history, co-occurring anxiety, trauma, substance use, bipolar features, medical conditions, and current medications.
Spravato may appeal to patients who want an FDA-approved treatment delivered in a structured outpatient setting with clear protocols and consistent monitoring. It may also be a strong fit for patients who want treatment coordinated closely by psychiatric specialists.
Ketamine may be considered when a patient is exploring off-label options, when a specific clinic has strong medical oversight, or when prior treatment factors make that route more appropriate. The fact that ketamine is off-label does not disqualify it. It simply raises the bar for choosing the right treatment team.
For many patients in Saginaw and nearby communities, access to specialist-led psychiatric care is part of the decision. A same-week evaluation, clear eligibility review, and a treatment plan that does not rely on guesswork can make the process feel far less overwhelming.
The most important question to ask before choosing
Ask who will be managing your depression before, during, and after treatment.
Rapid-acting therapies can be meaningful, but they work best when they are part of a larger plan. That plan may include medication management, ongoing psychiatric care, therapy, or other evidence-based options such as TMS. If symptoms improve, someone still needs to track whether that improvement lasts. If symptoms do not improve, someone should know what to adjust next.
That continuity matters just as much as the treatment itself. A supportive outpatient practice with board-certified psychiatric leadership, strong monitoring, and measurable follow-up can help patients move from crisis decision-making toward stable long-term care.
If you are comparing Spravato versus ketamine treatment, it is reasonable to want a treatment that offers breakthrough relief. It is just as reasonable to want that relief delivered with structure, medical credibility, and a plan built around you. The best next step is not chasing the newest option. It is choosing care that is safe, personalized, and steady enough to carry hope forward.